EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity

Christian Gege iD, Friedrich Hahn, Christina Wangen, Sigrun Häge, Alexandra Herrmann, Nadja Uhlig, Valentina Eberlein, Leila Issmail, Robert Klopfleisch, Thomas Grunwald, Manfred Marschall, Hella Kohlhof und 1 weitere

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Christian Gege und 12 weiteren Autor:innen. Beteiligte Einrichtung: Immunic AG, Lochhamer Schlag 21, 82166, Gräfelfing, Germany. Hauptthemen laut MEDLINE: Dihydroorotate Dehydrogenase, Antiviral Agents, SARS-CoV-2, Oxidoreductases Acting on CH-CH Group Donors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bavarian Research Foundation, Bayerische Forschungsstiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New strategies for the rapid development of broad‐spectrum antiviral therapies are urgently required for emerging and re‐emerging viruses like the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Host‐directed antivirals that target universal cellular metabolic pathways necessary for viral replication present a promising approach with broad‐spectrum activity and low potential for development of viral resistance. Dihydroorotate dehydrogenase (DHODH) was identified as one of those universal host factors essential for the replication of many clinically relevant human pathogenic viruses. DHODH is the rate‐limiting enzyme catalyzing the fourth step in the de novo pyrimidine synthesis. Therefore, it is also developed as a therapeutic target for many diseases relying on cellular pyrimidine resources, such as cancer, autoimmune diseases and viral or bacterial infection. Thus, several DHODH inhibitors, including vidofludimus calcium (VidoCa, IMU‐838), are currently in development or have been investigated in clinical trials for the treatment of virus infections such as SARS‐CoV‐2‐mediated coronavirus disease 19 (COVID‐19). Here, we report the medicinal chemistry optimization of VidoCa that resulted in metabolically more stable derivatives with improved DHODH target inhibition in various mammalian species, which translated into improved efficacy against SARS‐CoV‐2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydroorotate DehydrogenaseAntiviral AgentsSARS-CoV-2Oxidoreductases Acting on CH-CH Group DonorsEnzyme InhibitorsHumansCOVID-19 Drug TreatmentAnimalsStructure-Activity RelationshipMolecular StructureMicrobial Sensitivity Tests

Stichwörter der Autor:innen

COVID-19DHODHantiviral agentshost-directed antiviralshost-directed drug targetingvidofludimus calciumviruses

Substanzen

Dihydroorotate DehydrogenaseAntiviral AgentsOxidoreductases Acting on CH-CH Group DonorsEnzyme Inhibitors

Autor:innen und Institutionen

  • Immunic AG, Lochhamer Schlag 21, 82166, Gräfelfing, Germany.
  • Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054, Erlangen, Germany.
  • Department of Vaccines and Infection Models, Unit Preclinical Validation, Fraunhofer-Institute for Cell Therapy and Immunology IZI, Perlickstrasse 1, 04103, Leipzig, Germany.
  • Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, 14163, Berlin, Germany.

ORCID-Profile: Christian Gege

Förderung

  • Bavarian Research Foundation
  • Bayerische Forschungsstiftung

Zitieren

APA

Gege, C., Hahn, F., Wangen, C., Häge, S., Herrmann, A., Uhlig, N., Eberlein, V., Issmail, L., Klopfleisch, R., Grunwald, T., Marschall, M., Kohlhof, H., & Vitt, D. (2024). Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity. ChemMedChem. https://doi.org/10.1002/cmdc.202400292

Vancouver

Gege C, Hahn F, Wangen C, Häge S, Herrmann A, Uhlig N, et al. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity. ChemMedChem. 2024. doi:10.1002/cmdc.202400292

BibTeX
@article{Gege2024,
  author = {Gege, Christian and Hahn, Friedrich and Wangen, Christina and Häge, Sigrun and Herrmann, Alexandra and Uhlig, Nadja and Eberlein, Valentina and Issmail, Leila and Klopfleisch, Robert and Grunwald, Thomas and Marschall, Manfred and Kohlhof, Hella and Vitt, Daniel},
  title = {Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400292}
}
Kostenlos starten →